IP Library Granted Patent US 10,815,525
Granted Patent B2
US 10,815,525 · App. 16/439,675 · Granted Oct 27, 2020

Methods and systems for processing polynucleotides

Inventors: Michael Ybarra Lucero (South San Francisco, CA); Tarjei Sigurd Mikkelsen (Dublin, CA); Katherine Pfeiffer (Berkeley, CA); Stephane Claude Boutet (Pleasanton, CA)
Assignee: 10X GENOMICS, INC.
C12Q1/6874C12Q1/683C12Q1/6806C12Q2525/191C12Q2537/143C12Q2563/179
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,815,525
App. No.
16/439,675
Granted
Oct 27, 2020
Kind
B2
Abstract

The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing and analyte characterization. Such polynucleotide processing may be useful for a variety of applications, including analyte characterization by polynucleotide sequencing. The compositions, methods, systems, and devices disclosed herein generally describe barcoded oligonucleotides, which can be bound to a bead, such as a gel bead, useful for characterizing one or more analytes including, for example, protein (e.g., cell surface or intracellular proteins), genomic DNA, and RNA (e.g., mRNA or CRISPR guide RNAs). Also described herein, are barcoded labelling agents and oligonucleotide molecules useful for “tagging” analytes for characterization.

Claims (56)

1. A method for analyzing a tissue sample comprising:

(a) delivering a plurality of spatial oligonucleotides to a location in a tissue sample comprising cells, wherein a spatial oligonucleotide of the plurality of spatial oligonucleotides comprises (i) a spatial barcode sequence and (ii) a cell labeling agent configured to deliver the spatial oligonucleotide to a cell at the location in the tissue sample, thereby labeling the cell with the cell labeling agent to form a labeled cell;

(b) dissociating the tissue sample into a plurality of cells, wherein the plurality of cells comprises the labeled cell, and wherein the labeled cell comprises: (i) the spatial oligonucleotide and (ii) a plurality of analytes;

(c) partitioning the labeled cell and a plurality of cell barcode nucleic acid molecules into a partition, wherein each cell barcode nucleic acid molecule of the plurality of cell barcode nucleic acid molecules (i) comprises a common cell barcode sequence and (ii) is configured to couple to the spatial oligonucleotide and analytes of the plurality of analytes; and

(d) in the partition, generating (i) a spatial barcoded nucleic acid molecule comprising (1) the spatial barcode sequence or a complement thereof and (2) the common cell barcode sequence or a complement thereof, (ii) a first barcoded nucleic acid molecule corresponding to a first analyte of the plurality of analytes and comprising the common cell barcode sequence or a complement thereof, and (iii) a second barcoded nucleic acid molecule corresponding to a second analyte of the plurality of analytes and comprising the common cell barcode sequence or a complement thereof, wherein the first analyte is a different type of analyte than the second analyte.

2. The method of claim 1 , wherein a cell barcode nucleic acid molecule of the plurality of cell barcode nucleic acid molecules is configured to couple to the spatial oligonucleotide and the first analyte and the second analyte via a common capture sequence.

3. The method of claim 1 , further comprising removing (i) the spatial barcoded nucleic acid molecule or a complement thereof, (ii) the first barcoded nucleic acid molecule or a complement thereof, and (iii) the second barcoded nucleic acid molecule or a complement thereof from the partition.

4. The method of claim 3 , further comprising sequencing (i) the spatial barcoded nucleic acid molecule or the complement thereof to determine the spatial barcode sequence, thereby generating a determined spatial barcode sequence, (ii) the first barcoded nucleic acid molecule or the complement thereof to determine the common cell barcode sequence, thereby generating a first determined common cell barcode sequence, and (iii) the second barcoded nucleic acid molecule or the complement thereof to determine the common cell barcode sequence, thereby generating a second determined common cell barcode sequence.

5. The method of claim 4 , further comprising using (i) the determined spatial barcode sequence to identify the location in the tissue sample at which the cell was labeled, (ii) the first determined common cell barcode sequence to identify the first analyte as originating from the cell, and (iii) the second determined common cell barcode sequence to identify the second analyte as originating from the cell.

6. The method of claim 1 , wherein the plurality of cell barcode nucleic acid molecules is coupled to a support.

7. The method of claim 6 , wherein the support is a bead.

8. The method of claim 7 , wherein the bead is a gel bead.

9. The method of claim 6 , wherein, after (c), a cell barcode nucleic acid molecule of the plurality of cell barcode nucleic acid molecules is released from the support.

10. The method of claim 1 , wherein the cell labeling agent is selected from the group consisting of a lipid, a fluorophore, a dye, a peptide, an antibody, and a nanoparticle.

11. The method of claim 1 , wherein the first analyte is a protein.

12. The method of claim 1 , wherein the first analyte is a labeling agent configured to couple to a protein.

13. The method of claim 12 , wherein the protein is a cell surface protein.

14. The method of claim 1 , wherein the first analyte is a surface feature of a cell.

15. The method of claim 1 , wherein the first analyte and the second analyte are selected from the group consisting of a deoxyribonucleic acid (DNA) molecule, a ribonucleic acid (RNA) molecule, and an additional labelling agent configured to couple to a protein.

16. The method of claim 1 , wherein the labeled cell comprises the spatial oligonucleotide via the cell labeling agent.

17. The method of claim 1 , wherein the cell is a single cell.

18. The method of claim 1 , wherein the partition is among a plurality of partitions.

19. The method of claim 1 , wherein the partition is a droplet or a well.

20. The method of claim 1 , wherein the tissue sample is a tissue cross-section.

21. A method for analyzing a tissue sample comprising:

(a) delivering a plurality of spatial oligonucleotides to a location in a tissue sample comprising cells, wherein a spatial oligonucleotide of the plurality of spatial oligonucleotides comprises (i) a spatial barcode sequence and (ii) a cell labeling agent configured to deliver the spatial oligonucleotide to a cell at the location in the tissue sample, thereby labeling the cell with the cell labeling agent to form a labeled cell;

(b) dissociating the tissue sample into a plurality of cells, wherein the plurality of cells comprises the labeled cell, and wherein the labeled cell comprises: (i) the spatial oligonucleotide and (ii) a plurality of analytes;

(c) partitioning the labeled cell and a plurality of cell barcode nucleic acid molecules into a partition, wherein each cell barcode nucleic acid molecule of the plurality of cell barcode nucleic acid molecules comprises a common cell barcode sequence, and wherein a first cell barcode nucleic acid molecule of the plurality of cell barcode nucleic acid molecules and a second cell barcode nucleic acid molecule of the plurality of cell barcode nucleic acid molecules are each configured to couple to one or more of the spatial oligonucleotide, a first analyte of the plurality of analytes, and a second analyte of the plurality of analytes; and

(d) in the partition, generating (i) a spatial barcoded nucleic acid molecule comprising (1) the spatial barcode sequence or a complement thereof and (2) the common cell barcode sequence or a complement thereof, (ii) a first barcoded nucleic acid molecule corresponding to the first analyte and comprising the common cell barcode sequence or a complement thereof, and (iii) a second barcoded nucleic acid molecule corresponding to the second analyte and comprising the common cell barcode sequence or a complement thereof, wherein the first analyte is a different type of analyte than the second analyte.

22. The method of claim 21 , wherein the first cell barcode nucleic acid molecule is configured to couple to one of the spatial oligonucleotide, the first analyte, or the second analyte.

23. The method of claim 21 , wherein the second cell barcode nucleic acid molecule is configured to couple to one of the spatial oligonucleotide, the first analyte, or the second analyte.

24. The method of claim 21 , further comprising removing (i) the spatial barcoded nucleic acid molecule or a complement thereof, (ii) the first barcoded nucleic acid molecule or a complement thereof, and (iii) the second barcoded nucleic acid molecule or a complement thereof from the partition.

25. The method of claim 24 , further comprising sequencing (i) the spatial barcoded nucleic acid molecule or the complement thereof to determine the spatial barcode sequence, thereby generating a determined spatial barcode sequence, (ii) the first barcoded nucleic acid molecule or the complement thereof to determine the common cell barcode sequence, thereby generating a first determined common cell barcode sequence, and (iii) the second barcoded nucleic acid molecule or the complement thereof to determine the common cell barcode sequence, thereby generating a second determined common cell barcode sequence.

26. The method of claim 25 , further comprising using (i) the determined spatial barcode sequence to identify the location in the tissue sample at which the cell was labeled, (ii) the first determined common cell barcode sequence to identify the first analyte as originating from the cell, and (iii) the second determined common cell barcode sequence to identify the second analyte as originating from the cell.

27. The method of claim 21 , wherein the plurality of cell barcode nucleic acid molecules is coupled to a support.

28. The method of claim 21 , wherein the partition is among a plurality of partitions.

29. The method of claim 21 , wherein the partition is a droplet or a well.

30. The method of claim 21 , wherein the tissue sample is a tissue cross-section.

31. The method of claim 21 , wherein the first analyte and the second analyte are selected from the group consisting of a deoxyribonucleic acid (DNA) molecule, a ribonucleic acid (RNA) molecule, and an additional labelling agent configured to couple to a protein.

32. The method of claim 21 , wherein the first analyte or the second analyte is a metabolite.

33. The method of claim 21 , wherein the tissue sample is a fixed tissue sample.

34. The method of claim 21 , wherein the cell labeling agent is selected from the group consisting of a lipid, a fluorophore, a dye, a peptide, an antibody, and a nanoparticle.

35. The method of claim 21 , wherein the cell labeling agent comprises a lipophilic moiety.

36. The method of claim 35 , wherein the lipophilic moiety is selected from the group consisting of an amphiphilic molecule, a tocopherol or derivative thereof, a steryl lipid, lignoceric acid, and palmitic acid.

37. The method of claim 35 , wherein the lipophilic moiety is a cholesterol moiety.

38. The method of claim 21 , wherein the spatial oligonucleotide further comprises one or more functional sequences selected from the group consisting of a sequencing primer sequence, sequencer specific flow cell attachment sequence, a priming sequence, and a capture sequence.

39. The method of claim 21 , wherein the first cell barcode nucleic acid molecule or the second cell barcode nucleic acid molecule comprises one or more functional sequences selected from the group consisting of an adapter sequence, a primer sequence, a primer binding sequence, a unique molecular identification (UMI) sequence, and a sequence configured to couple to a flow cell of a sequencer.

40. The method of claim 21 , wherein the first cell barcode nucleic acid molecule or the second cell barcode nucleic acid molecule comprises a modification for blocking a primer extension reaction.

41. The method of claim 1 , wherein the first analyte or the second analyte is a metabolite.

42. The method of claim 1 , wherein the tissue sample is a fixed tissue sample.

43. The method of claim 1 , wherein the cell labeling agent comprises a lipophilic moiety.

44. The method of claim 43 , wherein the lipophilic moiety is selected from the group consisting of an amphiphilic molecule, a tocopherol or derivative thereof, a steryl lipid, lignoceric acid, and palmitic acid.

45. The method of claim 43 , wherein the lipophilic moiety is a cholesterol moiety.

46. The method of claim 1 , wherein the spatial oligonucleotide further comprises one or more functional sequencer specific flow cell attachment sequence, a priming sequence, and a capture sequence.

47. The method of claim 1 , wherein the first cell barcode nucleic acid molecule or the second cell barcode nucleic acid molecule comprises one or more functional sequences selected from the group consisting of an adapter sequence, a primer sequence, a primer binding sequence, a unique molecular identification (UMI) sequsence, and a sequence configured to couple to a flow cell of a sequencer.

48. The method of claim 1 , wherein the first cell barcode nucleic acid molecule or the second cell barcode nucleic acid molecule comprises a modification for blocking a primer extension reaction.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2019
From: BELGRADER, PHILLIP; BENT, ZACHARY; BHARADWAJ, RAJIV; GOPALAN, VIJAY KUMAR SREENIVASA; HARADA, JOSEPHINE; HINDSON, CHRISTOPHER; LENJI, MOHAMMAD RAHIMI; LUCERO, MICHAEL YBARRA; MCDERMOTT, GEOFFREY; MEER, ELLIOTT; MIKKELSEN, TARJEI SIGURD; O'KEEFFE, CHRISTOPHER JOACHIM; PFEIFFER, KATHERINE; PRICE, ANDREW D.; RYVKIN, PAUL; SAXONOV, SERGE; STUELPNAGEL, JOHN R.; TERRY, JESSICA MICHELE; WHEELER, TOBIAS DANIEL; WU, INDIRA; ZIRALDO, SOLONGO BATJARGAL; BOUTET, STEPHANE CLAUDE; TAYLOR, SARAH; SRINIVAS, NIRANJAN
To: 10X GENOMICS, INC.
Reel/Frame 050345/0324 →
Continuity (14)
Continuation In Part 15933299 · Mar 22, 2018
Continuation 15720085 · Sep 29, 2017
Continuation 16439675
Continuation In Part PCTUS2017068320 · Dec 22, 2017
Continuation In Part 15720085 · Sep 29, 2017
Continuation In Part 16439675
Continuation In Part PCTUS2018064600 · Dec 7, 2018
Continuation In Part 16107685 · Aug 21, 2018
Continuation In Part 16439675
Continuation In Part 16107685 · Aug 21, 2018
Provisional Application 62438341 · Dec 22, 2016
Provisional Application 62596557 · Dec 8, 2017
Provisional Application 62723960 · Aug 28, 2018
Related Publication 20200002763A1 · Jan 2, 2020
Cited By (30)
US 12,188,014 US 12,209,271 US 12,235,262 US 12,249,402 US 12,264,316 US 12,264,411 US 12,269,036 US 12,275,993 US 12,305,239 US 12,312,640 US 12,365,893 US 12,391,975 US 12,391,976 US 12,398,262 US 12,411,132 US 12,416,102 US 12,428,673 US 12,467,088 US 12,473,585 US 12,480,158 US 12,534,760 US 12,553,074 US 12,580,044 US 12,600,961 US 12,606,860 US 12,612,714 US 12,624,384 US 12,655,450 US 12,686,949 US 12,692,536